I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3ß signaling pathway

Etsuro Ohta, Tomoko Nihira, Akiko Uchino, Yoichi Imaizumi, Yohei Okada, Wado Akamatsu, Kayoko Takahashi, Hideki Hayakawa, Makiko Nagai, Manabu Ohyama, Masafuchi Ryo, Mieko Ogino, Shigeo Murayama, Akihiko Takashima, Kazutoshi Nishiyama, Yoshikuni Mizuno, Hideki Mochizuki, Fumiya Obata, Hideyuki Okano

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is the causative molecule of the autosomal dominant hereditary form of Parkinson's disease (PD), PARK8, which was originally defined in a study of a Japanese family (the Sagamihara family) harboring the I2020T mutation in the kinase domain. Although a number of reported studies have focused on cell death mediated by mutant LRRK2, details of the pathogenetic effect of LRRK2 still remain to be elucidated. In the present study, to elucidate the mechanism of neurodegeneration in PD caused by LRRK2, we generated induced pluripotent stem cells (iPSC) derived from fibroblasts of PD patients with I2020T LRRK2 in the Sagamihara family. We found that I2020T mutant LRRK2 iPSC-derived neurons released less dopamine than control-iPSC-derived neurons. Furthermore, we demonstrated that patient iPSC-derived neurons had a lower phospho-AKT level than control-iPSC-derived neurons, and that the former showed an increased incidence of apoptosis relative to the controls. Interestingly, patient iPSC-derived neurons exhibited activation of glycogen synthase kinase-3ß (GSK-3ß) and high Tau phosphorylation. In addition, the postmortem brain of the patient fromwhomthe iPSC had been established exhibited deposition of neurofibrillary tangles as well as increased Tau phosphorylation in neurons. These results suggest that I2020T LRRK2-iPSC could be a promising new tool for reproducing the pathology of PD in the brain caused by the I2020T mutation, and applicable as a model in studies of targeted therapeutics.

Original languageEnglish
Pages (from-to)4879-4900
Number of pages22
JournalHuman Molecular Genetics
Volume24
Issue number17
DOIs
Publication statusPublished - 2015

Fingerprint

Glycogen Synthase Kinase 3
Induced Pluripotent Stem Cells
Leucine
Phosphotransferases
Phosphorylation
Neurons
Parkinson Disease
Mutation
Neurofibrillary Tangles
Brain
Dopamine
Cell Death
Apoptosis
Pathology
Incidence

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3ß signaling pathway. / Ohta, Etsuro; Nihira, Tomoko; Uchino, Akiko; Imaizumi, Yoichi; Okada, Yohei; Akamatsu, Wado; Takahashi, Kayoko; Hayakawa, Hideki; Nagai, Makiko; Ohyama, Manabu; Ryo, Masafuchi; Ogino, Mieko; Murayama, Shigeo; Takashima, Akihiko; Nishiyama, Kazutoshi; Mizuno, Yoshikuni; Mochizuki, Hideki; Obata, Fumiya; Okano, Hideyuki.

In: Human Molecular Genetics, Vol. 24, No. 17, 2015, p. 4879-4900.

Research output: Contribution to journalArticle

Ohta, E, Nihira, T, Uchino, A, Imaizumi, Y, Okada, Y, Akamatsu, W, Takahashi, K, Hayakawa, H, Nagai, M, Ohyama, M, Ryo, M, Ogino, M, Murayama, S, Takashima, A, Nishiyama, K, Mizuno, Y, Mochizuki, H, Obata, F & Okano, H 2015, 'I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3ß signaling pathway', Human Molecular Genetics, vol. 24, no. 17, pp. 4879-4900. https://doi.org/10.1093/hmg/ddv212
Ohta, Etsuro ; Nihira, Tomoko ; Uchino, Akiko ; Imaizumi, Yoichi ; Okada, Yohei ; Akamatsu, Wado ; Takahashi, Kayoko ; Hayakawa, Hideki ; Nagai, Makiko ; Ohyama, Manabu ; Ryo, Masafuchi ; Ogino, Mieko ; Murayama, Shigeo ; Takashima, Akihiko ; Nishiyama, Kazutoshi ; Mizuno, Yoshikuni ; Mochizuki, Hideki ; Obata, Fumiya ; Okano, Hideyuki. / I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3ß signaling pathway. In: Human Molecular Genetics. 2015 ; Vol. 24, No. 17. pp. 4879-4900.
@article{7bb52d1680824bd6bf32cd5a0978048c,
title = "I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3{\ss} signaling pathway",
abstract = "Leucine-rich repeat kinase 2 (LRRK2) is the causative molecule of the autosomal dominant hereditary form of Parkinson's disease (PD), PARK8, which was originally defined in a study of a Japanese family (the Sagamihara family) harboring the I2020T mutation in the kinase domain. Although a number of reported studies have focused on cell death mediated by mutant LRRK2, details of the pathogenetic effect of LRRK2 still remain to be elucidated. In the present study, to elucidate the mechanism of neurodegeneration in PD caused by LRRK2, we generated induced pluripotent stem cells (iPSC) derived from fibroblasts of PD patients with I2020T LRRK2 in the Sagamihara family. We found that I2020T mutant LRRK2 iPSC-derived neurons released less dopamine than control-iPSC-derived neurons. Furthermore, we demonstrated that patient iPSC-derived neurons had a lower phospho-AKT level than control-iPSC-derived neurons, and that the former showed an increased incidence of apoptosis relative to the controls. Interestingly, patient iPSC-derived neurons exhibited activation of glycogen synthase kinase-3{\ss} (GSK-3{\ss}) and high Tau phosphorylation. In addition, the postmortem brain of the patient fromwhomthe iPSC had been established exhibited deposition of neurofibrillary tangles as well as increased Tau phosphorylation in neurons. These results suggest that I2020T LRRK2-iPSC could be a promising new tool for reproducing the pathology of PD in the brain caused by the I2020T mutation, and applicable as a model in studies of targeted therapeutics.",
author = "Etsuro Ohta and Tomoko Nihira and Akiko Uchino and Yoichi Imaizumi and Yohei Okada and Wado Akamatsu and Kayoko Takahashi and Hideki Hayakawa and Makiko Nagai and Manabu Ohyama and Masafuchi Ryo and Mieko Ogino and Shigeo Murayama and Akihiko Takashima and Kazutoshi Nishiyama and Yoshikuni Mizuno and Hideki Mochizuki and Fumiya Obata and Hideyuki Okano",
year = "2015",
doi = "10.1093/hmg/ddv212",
language = "English",
volume = "24",
pages = "4879--4900",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "17",

}

TY - JOUR

T1 - I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3ß signaling pathway

AU - Ohta, Etsuro

AU - Nihira, Tomoko

AU - Uchino, Akiko

AU - Imaizumi, Yoichi

AU - Okada, Yohei

AU - Akamatsu, Wado

AU - Takahashi, Kayoko

AU - Hayakawa, Hideki

AU - Nagai, Makiko

AU - Ohyama, Manabu

AU - Ryo, Masafuchi

AU - Ogino, Mieko

AU - Murayama, Shigeo

AU - Takashima, Akihiko

AU - Nishiyama, Kazutoshi

AU - Mizuno, Yoshikuni

AU - Mochizuki, Hideki

AU - Obata, Fumiya

AU - Okano, Hideyuki

PY - 2015

Y1 - 2015

N2 - Leucine-rich repeat kinase 2 (LRRK2) is the causative molecule of the autosomal dominant hereditary form of Parkinson's disease (PD), PARK8, which was originally defined in a study of a Japanese family (the Sagamihara family) harboring the I2020T mutation in the kinase domain. Although a number of reported studies have focused on cell death mediated by mutant LRRK2, details of the pathogenetic effect of LRRK2 still remain to be elucidated. In the present study, to elucidate the mechanism of neurodegeneration in PD caused by LRRK2, we generated induced pluripotent stem cells (iPSC) derived from fibroblasts of PD patients with I2020T LRRK2 in the Sagamihara family. We found that I2020T mutant LRRK2 iPSC-derived neurons released less dopamine than control-iPSC-derived neurons. Furthermore, we demonstrated that patient iPSC-derived neurons had a lower phospho-AKT level than control-iPSC-derived neurons, and that the former showed an increased incidence of apoptosis relative to the controls. Interestingly, patient iPSC-derived neurons exhibited activation of glycogen synthase kinase-3ß (GSK-3ß) and high Tau phosphorylation. In addition, the postmortem brain of the patient fromwhomthe iPSC had been established exhibited deposition of neurofibrillary tangles as well as increased Tau phosphorylation in neurons. These results suggest that I2020T LRRK2-iPSC could be a promising new tool for reproducing the pathology of PD in the brain caused by the I2020T mutation, and applicable as a model in studies of targeted therapeutics.

AB - Leucine-rich repeat kinase 2 (LRRK2) is the causative molecule of the autosomal dominant hereditary form of Parkinson's disease (PD), PARK8, which was originally defined in a study of a Japanese family (the Sagamihara family) harboring the I2020T mutation in the kinase domain. Although a number of reported studies have focused on cell death mediated by mutant LRRK2, details of the pathogenetic effect of LRRK2 still remain to be elucidated. In the present study, to elucidate the mechanism of neurodegeneration in PD caused by LRRK2, we generated induced pluripotent stem cells (iPSC) derived from fibroblasts of PD patients with I2020T LRRK2 in the Sagamihara family. We found that I2020T mutant LRRK2 iPSC-derived neurons released less dopamine than control-iPSC-derived neurons. Furthermore, we demonstrated that patient iPSC-derived neurons had a lower phospho-AKT level than control-iPSC-derived neurons, and that the former showed an increased incidence of apoptosis relative to the controls. Interestingly, patient iPSC-derived neurons exhibited activation of glycogen synthase kinase-3ß (GSK-3ß) and high Tau phosphorylation. In addition, the postmortem brain of the patient fromwhomthe iPSC had been established exhibited deposition of neurofibrillary tangles as well as increased Tau phosphorylation in neurons. These results suggest that I2020T LRRK2-iPSC could be a promising new tool for reproducing the pathology of PD in the brain caused by the I2020T mutation, and applicable as a model in studies of targeted therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84941886639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941886639&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddv212

DO - 10.1093/hmg/ddv212

M3 - Article

VL - 24

SP - 4879

EP - 4900

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 17

ER -